Spinal cord injury (SCI) often leads to lifelong paralysis or loss of sensation below the injury site. Traditional surgery and rehabilitation can stabilize the spine but rarely restore nerve function.
Recent breakthroughs in stem-cell research, especially using Umbilical-Cord-Derived Mesenchymal Stem Cells (UC-MSCs), are changing that outlook. At EDNA Wellness, our regenerative-medicine programs align with these global developments, using GMP-certified UC-MSCs to ensure scientific credibility and patient safety.
Understanding Spinal Cord Injury (SCI)
An SCI occurs when trauma, infection, or ischemia damages the spinal cord’s nerve fibers. Depending on the level of injury:
- Complete SCI → total loss of motor and sensory function below the injury.
- Incomplete SCI → partial movement or sensation remains.
Major causes include traffic accidents, sports injuries, or spinal tumors. In Thailand, nearly 80 % of cases involve young adults aged 18–40, highlighting the need for regenerative, long-term solutions.
Limitations of Conventional Treatment
- Surgery stabilizes the spine but cannot repair neurons.
- Medication controls pain and spasticity but does not promote nerve regrowth.
- Rehabilitation strengthens remaining muscles but cannot restore lost connections.
Because neurons in the central nervous system rarely regenerate, researchers have turned to stem cells to create a biological healing environment.
How UC-MSCs Work in SCI Recovery
UC-MSCs don’t simply replace neurons — they reprogram the healing environment:
- Neuroprotection – release growth factors (BDNF, NGF, VEGF) that prevent neuronal death.
- Anti-inflammatory action – suppress microglial activation and toxic cytokines.
- Angiogenesis – improve oxygen delivery by forming new micro-vessels.
- Myelin repair – promote oligodendrocyte survival to restore signal conduction.
- Axonal guidance – release exosomes that help regrow neural pathways
These effects enable functional improvement even years after injury.
Global Research Highlights (2023 – 2025)
| Region / Study | Design | Key Findings |
| China (2023) | Phase II clinical trial of intrathecal UC-MSCs in chronic SCI | 65 % of patients gained partial motor function (Liu et al., 2023). |
| Japan (2024) | Combined UC-MSC + rehabilitation protocol | Significant improvement in sensation and spasticity (Yamamoto et al., 2024). |
| United States (2025) | UC-MSC-derived exosome therapy (Phase I) | Safe delivery with early evidence of axon sprouting (Anderson et al., 2025). |
| Europe (2024) | Intravenous UC-MSC for incomplete SCI | Enhanced blood flow and muscle tone without immune rejection (Wang et al., 2024). |
Together these studies demonstrate consistent functional recovery and excellent safety records worldwide.
Treatment Methods Used in Clinical Research
| Route | Purpose | Advantages | Limitations |
| Intrathecal (Spinal) | Deliver cells into cerebrospinal fluid | Direct contact with injured cord | Requires lumbar puncture |
| Intravenous (IV) | Systemic immune modulation | Minimally invasive, safe | Fewer cells reach lesion |
| Local Injection (Experimental) | Directly at injury site | High local concentration | Surgical risk |
At EDNA Wellness, we apply the clinically validated IV and intrathecal routes only, with strict cell-count verification and post-treatment monitoring.
Safety Profile
- UC-MSCs are non-tumorigenic and low-immunogenic.
- Side effects (mild headache or fatigue) occur in < 5 % of cases.
- No serious adverse events reported in multi-year follow-ups
- All cells at EDNA Wellness undergo sterility, endotoxin, and viability testing in TISTR labs
Patients receive care under Thai FDA guidelines for cell and gene therapy, ensuring safety and documentation.
Expected Functional Improvements
- Months 1–3: Reduced spasticity, better sleep, lower neuropathic pain.
- Months 3–6: Return of partial sensation or muscle twitch in incomplete SCI.
- Months 6–12: Improved core balance and assisted mobility in responders.
Results depend on injury level and rehabilitation consistency. At EDNA Wellness, every program includes follow-up assessment and physical therapy support
Integration with Rehabilitation
Stem-cell therapy is most effective when paired with rehabilitation strategies:
- Physiotherapy to re-educate muscles.
- Occupational therapy to restore daily activities.
- Functional electrical stimulation (FES) to strengthen neural pathways.
- Nutritional programs to support cellular healing.
EDNA Wellness integrates these elements into a comprehensive care model.
Cautions for Patients
- Verify your doctor’s specialty in neurology or regenerative medicine.
- Request proof of GMP and TISTR certification for every batch.
- Avoid clinics offering “miracle cure in weeks.”
- Ensure rehabilitation is included for maximum effectiveness.
EDNA Wellness prioritizes transparency and ethical practice at every stage.
The Future of Spinal Regeneration
By 2025, research is advancing toward:
- 3D-bioprinted spinal scaffolds seeded with UC-MSCs.
- Gene-enhanced MSCs producing higher levels of GDNF and BDNF.
- MSC-derived exosome therapy for non-cell delivery systems.
Thailand’s regenerative community, supported by Mahidol University and TISTR, is actively collaborating to translate these discoveries into safe clinical practice
Spinal cord injury no longer means a life without hope. Global studies show that UC-MSC therapy can reduce inflammation, stimulate neural repair, and improve quality of life when combined with rehabilitation.
At EDNA Wellness, we bring these scientific breakthroughs to Thailand through certified laboratories, ethical clinical protocols, and personalized patient care.
About EDNA Wellness
EDNA Wellness is a private clinic specializing in Stem Cell Therapy in Bangkok, Thailand for Neurology & Stroke as well as Bones & Joints. Beyond rehabilitation, we also provide aesthetic and wellness treatments to support your full-body vitality. All delivered with expert care and compassion
For more information or inquiries, contact us via
LINE @ednawellness
WhatsApp +66 (0) 64 505 5599
References
- Anderson, J., Smith, R., & Fischer, A. (2025). Exosome-based stem-cell therapy for spinal cord injury: Early phase clinical results. Nature Biomedical Engineering, 9(1), 44–53.*
- Kim, H. J., Park, Y. M., & Choi, Y. (2023). Mesenchymal stem cells promote axonal regeneration in spinal cord injury via trophic factor secretion. Stem Cell Research & Therapy, 14(4), 330–342.*
- Liu, J., Wang, P., & Shen, B. (2023). Clinical outcomes of umbilical-cord MSC transplantation in chronic spinal cord injury: A phase II study. Neural Regeneration Research, 18(11), 2410–2419.*
- Wang, L., Zhao, Y., & Xu, Q. (2024). Mesenchymal stem-cell therapy for spinal cord injury: A systematic review and meta-analysis. Stem Cell Reviews and Reports, 20(3), 441–458.*
- Yamamoto, K., Sato, M., & Mori, H. (2024). UC-MSC combined with rehabilitation improves motor function after spinal cord injury. Frontiers in Neurology, 15, 108–120.*